Codexis, Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. Codexis develops engineered biocatalysts and related services, primarily for pharmaceutical manufacturing, and is expanding into fine chemicals. It also has an early-stage oral enzyme candidate for phenylketonuria (PKU).
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $35.3 million | $31.9 million |
| Biocatalyst product revenue | $13.1 million | $20.4 million |
| Research and development revenue | $14.9 million | $6.9 million |
| Revenue-sharing revenue | $7.3 million | $4.6 million |
| Product gross margin | 26% | 29% |
| Research and development expense | $22.8 million | $31.6 million |
| Selling, general and administrative expense | $21.9 million | $26.9 million |
| Operating loss | $19.1 million | $41.1 million |
| Net loss | $19.1 million | $41.3 million |
| Net loss per share | $0.50 | $1.08 |
| Cash provided by (used in) operations | $0.3 million | $(23.0) million |
| Cash, cash equivalents and short-term investments | $26.5 million | $25.1 million |
| Working capital | $19.3 million | $24.6 million |
| Total liabilities | $21.8 million | $17.4 million |
Fourth-quarter 2014 revenue was $14.2 million and net income was $0.3 million, compared with revenue of $9.5 million and a net loss of $9.8 million in fourth-quarter 2013. The annual filing does not provide a clear debt balance or debt metric; the balance sheet reports total liabilities of $21.8 million. Contractual operating lease payments totaled $14.0 million, including $2.7 million due within one year.
Changes versus prior periods
- Revenue grew 11% year over year, as higher research and development and revenue-sharing revenue more than offset lower product sales.
- Product revenue fell 36%, primarily following the loss of $6.2 million in hepatitis C-related sales and a $1.4 million decline in statin-family sales amid generic competition. Product gross margin declined to 26%, mainly due to sales mix.
- Research and development revenue increased 118%, including a $5.0 million GSK milestone and increased customer services. GSK and Merck together accounted for 41% of 2014 revenue; the top three customers—Merck, Exela and GSK—accounted for 62%.
- Operating expenses declined 26%, reflecting restructuring, reduced headcount and lower research spending after the company wound down its CodeXyme cellulase and CodeXol detergent-alcohol programs. The annual net loss narrowed by $22.2 million.
- Operating cash flow improved to positive $0.3 million from negative $23.0 million. This occurred despite the annual net loss and included substantial non-cash expenses and a $4.2 million increase in deferred revenue; it should not be read as evidence of recurring profitability.
Outlook, material developments and risks
- Liquidity outlook: Management stated that existing cash and investments were expected to fund ongoing operations, planned capital expenditures and working capital needs for at least 12 months from the filing. The company continued to incur losses and warned that additional capital could be needed if plans or assumptions change.
- GSK license: Codexis received a $6.0 million upfront fee and a $5.0 million milestone in 2014. It may receive up to a further $14.0 million tied to technology-transfer milestones, additional project-based contingent payments and royalties on certain products. Much of the upfront fee is recognized over a three-year technology-transfer period; future contingent payments depend on transfer progress and GSK development or commercial success.
- PKU program: Animal-model studies showed reduced blood phenylalanine. Codexis was seeking a development partner and expected to begin IND-enabling studies in 2015; clinical development and regulatory approval remain uncertain.
- Manufacturing and customer concentration: Large-scale enzyme production depends substantially on contract manufacturer Lactosan. Codexis disclosed viral contamination and manufacturing delays there in the second half of 2014. Customer and product concentration, as well as possible reductions in Exela argatroban revenue following patent-related competition, create revenue volatility risk.
- Unusual items: Codexis sold its Hungarian subsidiary for $1.5 million and recorded a $0.8 million gain. It also recorded $2.7 million of 2014 research and development impairment charges, primarily relating to CodeXol assets and equipment. The 2014 tax benefit was $0.3 million; the company maintained a full valuation allowance against most deferred tax assets.
- Contingencies and controls: No material litigation was reported. A possible foreign VAT obligation of approximately $0.6 million was disclosed without an accrual. Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2014; the financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether GSK technology-transfer milestones are achieved, and how much revenue and cash are recognized from the agreement versus deferred.
- Whether product sales stabilize after hepatitis C and statin-family declines, and whether revenue-sharing income from Exela is sustained.
- Whether Codexis can diversify its customer base and reduce dependence on Lactosan, including validating alternative manufacturing capacity.
- Whether operating cash flow remains positive after the timing effects of deferred revenue and other working-capital changes, and whether the stated 12-month liquidity outlook remains adequate.
- Progress, partnership funding and costs for PKU IND-enabling work, as well as commercial traction in fine chemicals.
- The outcome of the potential $0.6 million VAT exposure and any further asset impairments or restructuring costs.